Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read More
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various forms of Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical to intercede in disease processes. Alterity is located in Melbourne, Australia and San Francisco, California, USA. The Company is listed on the Australian Securities Exchange (ASX: ATH) and NASDAQ (NASDAQ: ATHE).
Investment Highlights
- Strong and highly experienced board and management team with significant R&D and commercialisation experience including 3 drug approvals by US FDA.
- ATH434 is a novel drug candidate targeting key proteins implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism.
- ATH434 has completed its Phase 1 clinical trial program.
- First therapeutic target selected – Multiple System Atrophy (MSA), a form of atypical parkinsonism, is a devastating disease with no approved treatments.
- FDA Orphan Drug designation in the U.S. and EU for ATH434 for the treatment of MSA received.
- Significant market potential in MSA – estimated peak sales of US$725M.
Investor Resources
Corporate presentations
| March 23, 2023 | Corporate Presentation March 2023 | 4 MB | |
| March 14, 2023 | ShareCafe Presentation – March 2023 | 1 MB |
ASX Announcements
2022
2021
2020
2019
2018
| February 10, 2019 | Appendix 3B – Cleansing Notice – Feb 2018 | 362 KB | |
| January 7, 2019 | Form 603 – Notice of Initial Substantial Holder Morgan Stanley – Jan 2018 | 543 KB | |
| January 7, 2019 | Form 603 – Notice of Initial Substantial Holder MUFG – Jan 2018 | 457 KB | |
| January 7, 2019 | Appendix 3B – Jan 2018 | 955 KB | |
| December 23, 2018 | PBT Trading Halt – Dec 2018 | 459 KB | |
| December 4, 2018 | Form S-8 Dec 2018 | 271 KB | |
| November 19, 2018 | Appendix 3B – Nov 2018 | 940 KB | |
| November 19, 2018 | Appendix 3Y Change of Director’s Interest Notice – Nov 2018 | 456 KB | |
| November 16, 2018 | Results of AGM 2018 | 186 KB | |
| November 16, 2018 | AGM Presentation – Nov 2018 | 621 KB | |
| October 16, 2018 | Notice of AGM – Oct 2018 | 849 KB | |
| July 16, 2018 | Appendix 3B and 708A Notice – Jul 2018 | 248 KB | |
| June 27, 2018 | Investor Presentation – Jun 2018 | 5 MB | |
| January 22, 2018 | Appendix 3B – Jan 2018 | 809 KB |
Financial reports
2022
| October 28, 2022 | Appendix 4C – Q1 FY 2023 Quarterly Cash Flow Report – 28 October 2022 | 662 KB | |
| October 28, 2022 | Appendix 4C – Q4 FY 2022 Quarterly Cash Flow Report – 22 July 2022 | 649 KB | |
| September 1, 2022 | Form 20-F 2022 | 850 KB | |
| September 1, 2022 | ATH Annual Report 2022 | 2 MB | |
| April 29, 2022 | Appendix 4C – Q3 FY 2022 Quarterly Cash Flow Report – 29 April 2022 | 1 MB | |
| January 27, 2022 | Appendix 4C – Q2 FY22 Quarterly Cash Flow Report – 27 January 2022 | 422 KB |
2021
| June 24, 2022 | Half Year Financial Report Period to 31 Dec 2021 | 388 KB | |
| October 29, 2021 | Appendix 4C – September 2021 | 2 MB | |
| September 3, 2021 | Form 20-F 2021 | 776 KB | |
| September 1, 2021 | Annual Report 2021 | 3 MB | |
| July 30, 2021 | Appendix 4C-June 2021 | 411 KB | |
| April 29, 2021 | Appendix 4C – March 2021 | 418 KB | |
| February 25, 2021 | Appendix 4D 2020 | 374 KB |
2020
| January 29, 2021 | Appendix 4C- December 2020 | 339 KB | |
| October 30, 2020 | Appendix 4C- September 2020 | 354 KB | |
| September 16, 2020 | Form 20-F 2020 | 2 MB | |
| September 9, 2020 | Appendix 4G Ended 30 June 2020 | 374 KB | |
| September 9, 2020 | Annual Report 2020 | 2 MB | |
| August 31, 2020 | Appendix 4E Year ended 30 June 2020 | 454 KB | |
| July 30, 2020 | Appendix 4C – June 2020 | 384 KB | |
| April 30, 2020 | Appendix 4C – March 2020 | 346 KB | |
| February 28, 2020 | Form 6-K Feb 2020 | 233 KB | |
| February 28, 2020 | Appendix 4D 2019 | 410 KB | |
| January 31, 2020 | Appendix 4C – December 2019 | 372 KB |
2019
| October 30, 2019 | Appendix 4C – September 2019 | 346 KB | |
| September 2, 2019 | Form 20-F 2019 | 828 KB | |
| August 30, 2019 | Appendix 4G FY Ended 2019_06_30 | 341 KB | |
| August 30, 2019 | Annual Report 2019 | 1 MB | |
| August 1, 2019 | Appendix 4C – June 2019 | 151 KB | |
| May 13, 2019 | Form-6-K-2019_03_01 | 400 KB | |
| April 16, 2019 | Appendix 4C – Mar 2019 | 161 KB | |
| February 28, 2019 | Form 6-K – Mar 2019 | 400 KB | |
| February 28, 2019 | Appendix 4D 2018 | 217 KB | |
| January 31, 2019 | Appendix 4C – Dec 2018 | 234 KB |
2018
| May 13, 2019 | Form 6-K Feb 2018 | 148 KB | |
| October 30, 2018 | Appendix 4C – Sept 2018 | 170 KB | |
| September 3, 2018 | Form 20F – 2018 | 2 MB | |
| August 31, 2018 | Appendix 4G FY Ended 2018_06_30 | 123 KB | |
| August 31, 2018 | Annual Report 2018 | 2 MB | |
| July 30, 2018 | Appendix 4C – Jun 2018 | 262 KB | |
| May 7, 2018 | Appendix 4C – Mar 2018 | 263 KB | |
| March 4, 2018 | Form 6-K Feb 2018 | 148 KB |
Corporate governance
| November 16, 2022 | Alterity Therapeutics Constitution (Amended November 2022) | 445 KB | |
| September 13, 2022 | Communication and Disclosure Policy | 130 KB | |
| September 13, 2022 | Anti-Bribery and Anti-Corruption Policy | 150 KB | |
| September 13, 2022 | Securities Trading Policy | 182 KB | |
| September 1, 2022 | Corporate Governance Statement 2022 | 216 KB | |
| April 29, 2020 | Board Charter | 1 MB | |
| May 15, 2019 | Whistle Blower Policy | 320 KB | |
| May 15, 2019 | Diversity Policy | 197 KB | |
| November 23, 2020 | 2018 ADS Plan (as amended) | 100 KB | |
| November 23, 2020 | 2004 ASX Plan (as amended) | 52 KB |
News
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office
– Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson’s and Alzheimer’s – A
Read MoreChairman’s Address 2022 Annual General Meeting
Good morning all and thank you for joining us today for our FY22 Annual General Meeting. I’m pleased to share with you my chairman’s add
Read MoreAlterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read MoreAppendix 4C – Q1 FY23 Quarterly Cash Flow Report
First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand, trial opens in Europe and Australia Approval of Investigational New
Read MoreAlterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read More
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity
Read More
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity
Read MoreAppendix 4C – Q4 FY22 Quarterly Cash Flow Report
Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins Regulatory approval from the U.K. and Italian regula
Read More Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read MoreAlterity receives a $4.1 million R&D Tax Incentive Refund
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developin
Read MoreAlterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read More
Appendix 4C – Q1 FY22 Quarterly Cash Flow Report
Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disord
Read More
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read MoreAlterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
– Composition of matter patent from USPTO covers more than 100 novel compounds targeting neurodegenerative diseases including Alzheimer’
Read MoreShareCafe Investor Webinar Recording
Alterity Therapeutics’ CEO Dr David Stamler presented in the ShareCafe Small Cap “Hidden Gems” Webinar last Friday 10th of
Read MoreReceive news from Alterity Therapeutics
